These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32213304)

  • 1. Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients.
    Ismail FF; Meah N; Trindade de Carvalho L; Bhoyrul B; Wall D; Sinclair R
    J Am Acad Dermatol; 2020 Nov; 83(5):1478-1479. PubMed ID: 32213304
    [No Abstract]   [Full Text] [Related]  

  • 2. Bicalutamide.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
    Takeshita H; Kawakami S; Fukui I
    Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Van Poppel H
    Eur Urol; 2007 Jul; 52(1):115. PubMed ID: 17270341
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined androgen blockade for salivary gland carcinoma.
    Gourd E
    Lancet Oncol; 2018 Jan; 19(1):e17. PubMed ID: 29233558
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
    Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological Features and Treatment Challenges in Triple Negative Breast Cancer Patients: A Retrospective Cohort Study.
    Elwan A; Abdelrahman AE; Alnagar AA; Abdelhamid MI; Nawar N
    Turk Patoloji Derg; 2021; 37(2):121-129. PubMed ID: 33432555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy Plus GnRH Analogue
    Buwenge M; Deodato F; Macchia G; Siepe G; Zhao X; Valicenti RK; Cilla S; Alitto AR; Ntreta M; Bisello S; Mantini G; Valentini V; Morganti AG; Cammelli S
    Anticancer Res; 2019 Nov; 39(11):6373-6378. PubMed ID: 31704870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.
    Zanardi S; Puntoni M; Maffezzini M; Bandelloni R; Mori M; Argusti A; Campodonico F; Turbino L; Branchi D; Montironi R; Decensi A
    Cancer Prev Res (Phila); 2009 Apr; 2(4):377-84. PubMed ID: 19336728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor.
    Mitre N; Lteif A
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1163-7. PubMed ID: 20333877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bicalutamide for female pattern hair loss: A pilot study.
    Fernandez-Nieto D; Saceda-Corralo D; Rodrigues-Barata R; Hermosa-Gelbard A; Moreno-Arrones O; Jimenez-Cauhe J; Ortega-Quijano D; Vano-Galvan S
    Dermatol Ther; 2019 Nov; 32(6):e13096. PubMed ID: 31579984
    [No Abstract]   [Full Text] [Related]  

  • 13. Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
    Ferrari AC; Alumkal JJ; Stein MN; Taplin ME; Babb J; Barnett ES; Gomez-Pinillos A; Liu X; Moore D; DiPaola R; Beer TM
    Clin Cancer Res; 2019 Jan; 25(1):52-63. PubMed ID: 30224345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Fradet Y; Egerdie B; Andersen M; Tammela TL; Nachabe M; Armstrong J; Morris T; Navani S
    Eur Urol; 2007 Jul; 52(1):106-14. PubMed ID: 17270340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial pneumonitis induced by bicalutamide given for prostate cancer.
    Masago T; Watanabe T; Nemoto R; Motoda K
    Int J Clin Oncol; 2011 Dec; 16(6):763-5. PubMed ID: 21537882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
    Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
    Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.
    Cowan AJ; Inoue Y; Yu EY
    Clin Genitourin Cancer; 2015 Feb; 13(1):e51-3. PubMed ID: 25450034
    [No Abstract]   [Full Text] [Related]  

  • 19. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy.
    Choi KH; Lee SR; Hong YK; Park DS
    Asian J Androl; 2018; 20(3):270-275. PubMed ID: 29271399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.